$3.03 Billion is the total value of BRAIDWELL LP's 81 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 63.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Buy | NOVOCURE LTDnote 11/0 | $116,802,148 | -0.7% | 134,334,000 | +1.9% | 3.85% | -2.2% | |
| Buy | BRIDGEBIO PHARMA INCnote 2.500% 3/1 | $106,213,458 | +66.8% | 143,338,000 | +1.3% | 3.50% | +64.2% | |
| GKOS | Buy | GLAUKOS CORP | $90,513,215 | +24.7% | 1,806,651 | +8.7% | 2.98% | +22.7% |
| ISEE | Buy | IVERIC BIO INC | $90,377,970 | +26.3% | 3,714,672 | +11.2% | 2.98% | +24.4% |
| NBIX | New | NEUROCRINE BIOSCIENCES INC | $77,615,496 | – | 766,800 | +100.0% | 2.56% | – |
| XENE | Buy | XENON PHARMACEUTICALS INC | $76,487,167 | +25.3% | 2,137,110 | +38.0% | 2.52% | +23.3% |
| NVRO | Buy | NEVRO CORP | $59,029,877 | +25.0% | 1,632,915 | +37.0% | 1.95% | +23.1% |
| Buy | TRAVERE THERAPEUTICS INCnote 2.500% 9/1 | $53,901,491 | +15.5% | 56,031,000 | +10.9% | 1.78% | +13.8% | |
| Buy | NUVASIVE INCnote 1.000% 6/0 | $51,148,812 | +215.1% | 51,500,000 | +212.1% | 1.69% | +210.1% | |
| DAWN | Buy | DAY ONE BIOPHARMACEUTICALS I | $42,247,796 | +57.5% | 3,159,895 | +153.5% | 1.39% | +54.9% |
| ENTA | Buy | ENANTA PHARMACEUTICALS INC | $41,989,256 | +177.0% | 1,038,310 | +218.7% | 1.38% | +172.6% |
| AMGN | Buy | AMGEN INC | $39,042,625 | +13.4% | 161,500 | +23.2% | 1.29% | +11.6% |
| OM | Buy | OUTSET MED INC | $32,280,040 | -26.7% | 1,754,350 | +2.9% | 1.06% | -27.8% |
| HROW | New | HARROW HEALTH INC | $30,735,704 | – | 1,452,538 | +100.0% | 1.01% | – |
| BLU | Buy | BELLUS HEALTH INC NEW | $29,708,597 | -12.1% | 4,126,194 | +0.3% | 0.98% | -13.5% |
| Buy | DICE THERAPEUTICS INC | $28,214,520 | +7.8% | 984,800 | +17.4% | 0.93% | +6.2% | |
| ACRS | Buy | ACLARIS THERAPEUTICS INC | $26,446,970 | -29.9% | 3,269,094 | +36.6% | 0.87% | -31.0% |
| TERN | New | TERNS PHARMACEUTICALS INC | $23,645,131 | – | 1,997,055 | +100.0% | 0.78% | – |
| ANAB | Buy | ANAPTYSBIO INC | $21,174,068 | -5.9% | 973,073 | +34.0% | 0.70% | -7.4% |
| IMCR | New | IMMUNOCORE HLDGS PLCads | $21,066,878 | – | 426,110 | +100.0% | 0.70% | – |
| ALEC | Buy | ALECTOR INC | $19,847,090 | +196.6% | 3,206,315 | +342.2% | 0.66% | +192.4% |
| New | PARAGON 28 INC | $18,755,185 | – | 1,098,722 | +100.0% | 0.62% | – | |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $16,805,360 | -10.3% | 452,000 | +9.3% | 0.55% | -11.8% |
| BCRX | New | BIOCRYST PHARMACEUTICALS INC | $16,222,418 | – | 1,945,134 | +100.0% | 0.54% | – |
| DYN | Buy | DYNE THERAPEUTICS INC | $15,873,085 | +81.8% | 1,377,872 | +82.9% | 0.52% | +78.8% |
| VIR | New | VIR BIOTECHNOLOGY INC | $14,055,918 | – | 604,036 | +100.0% | 0.46% | – |
| MRSN | Buy | MERSANA THERAPEUTICS INC | $13,792,359 | +26.4% | 3,355,805 | +80.2% | 0.46% | +24.3% |
| PACB | New | PACIFIC BIOSCIENCES CALIF IN | $12,706,734 | – | 1,097,300 | +100.0% | 0.42% | – |
| CMPX | Buy | COMPASS THERAPEUTICS INC | $10,620,460 | +16.4% | 3,247,847 | +79.0% | 0.35% | +14.4% |
| New | ARCELLX INC | $10,284,378 | – | 333,800 | +100.0% | 0.34% | – | |
| AXNX | New | AXONICS INC | $9,095,370 | – | 166,704 | +100.0% | 0.30% | – |
| New | MINERALYS THERAPEUTICS INC | $8,617,698 | – | 550,300 | +100.0% | 0.28% | – | |
| ADPT | New | ADAPTIVE BIOTECHNOLOGIES COR | $5,725,822 | – | 648,451 | +100.0% | 0.19% | – |
| ALXO | Buy | ALX ONCOLOGY HLDGS INC | $5,649,548 | +94.1% | 1,249,900 | +383.9% | 0.19% | +89.8% |
| New | ILLUMINA INCnote 8/1 | $1,087,736 | – | 11,100,000 | +100.0% | 0.04% | – | |
| New | AVALO THERAPEUTICS INC | $432,695 | – | 247,254 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GUARDANT HEALTH INC | 4 | Q3 2023 | 6.3% |
| EXACT SCIENCES CORP | 4 | Q3 2023 | 4.4% |
| NOVOCURE LTD | 4 | Q3 2023 | 3.9% |
| NANOSTRING TECHNOLOGIES INC | 4 | Q3 2023 | 4.0% |
| NEVRO CORP | 4 | Q3 2023 | 3.4% |
| BRIDGEBIO PHARMA INC | 4 | Q3 2023 | 3.5% |
| ALPHATEC HLDGS INC | 4 | Q3 2023 | 3.6% |
| GLAUKOS CORP | 4 | Q3 2023 | 3.0% |
| VAXCYTE INC | 4 | Q3 2023 | 2.8% |
| XENON PHARMACEUTICALS INC | 4 | Q3 2023 | 2.5% |
View BRAIDWELL LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G | 2023-02-14 |
| SC 13G | 2023-02-14 |
| SC 13G | 2023-02-14 |
View BRAIDWELL LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.